COVID-19: Companies’ further solutions
Ten post jest także dostępny w języku: polski
Genomtec is not resting on its laurels and presents its next idea. The COVID-19 test from the patient’s saliva is to be available for sale in May this year. More COVID-19 vaccines are also being developed around the world. On May 17, Sanofi and GSK announced that their COVID-19 vaccine candidate was displaying a strong immune response.
COVID-19 vaccine from Sanofi and GSK
The product was developed as part of a collaboration between Sanofi and UK-based GlaxoSmithKline. The adjuvanted COVID-19 vaccine has already undergone two phases of testing. Preliminary results from a phase 2 study involving 722 participants showed that the vaccine showed 95% to 100% seroconversion following a second injection in all age groups (18 to 95 years old) and across all doses, with acceptable tolerability and with no safety concerns. As Sanofi states in an official statement, before it enters the market, however, it must pass the final key third phase of research. The study is planned over the next few weeks. Over 35,000 people are to take part in it. Following positive results, the vaccine has a chance to enter the global market commercially in late 2021.
It is worth mentioning that at present, almost 16.4 million vaccinations have been performed in Poland. More than 314,000 of them are performed daily. Furthermore, in Poland, a special team was established to track mutations of the COVID-19 virus. It took place on 10 May 2021, and the main purpose of its establishment is to study new mutations of the virus appearing in the country and to monitor them, including the Indian mutation.
Test for detection of COVID-19 from saliva from Genomtec
In May 2021, Genomtec will introduce the world’s first genetic test for the detection of COVID-19 from saliva. This test has already been registered and will be marketed in the European Union. In Poland, it will be possible to perform it in the Dolmed laboratory in Wrocław. The test result will be known only several dozen minutes after its execution.
It is worth adding that in addition to this COVID-19 test, Genomtec is also working on a set of primers and diagnostic panels to diagnose Lyme disease. In May this year, Genomtec obtained a patent for these solutions. As reported, this is the company’s third patent. In total, Genomtec is in the process of 20 patent proceedings worldwide.